Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Risitano, Antonio
GITMO-PHYLOS, NCT03270748: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies	Completed	2	78	Europe	GvHD prophylaxis	Gruppo Italiano Trapianto di Midollo Osseo	Myeloid Malignancies	11/22	11/22
NCT05002777 / 2021-001671-16: Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)	Active, not recruiting	2	22	Europe, US, RoW	rilzabrutinib, PRN1008/SAR444671	Sanofi, Sanofi Aventis Recherche et Developpement	Warm Autoimmune Hemolytic Anemia (wAIHA)	05/24	05/25
RACE2, NCT05049668: RACE 2: a Long Term Follow-up of Patients Participating in the RACE Trial	Enrolling by invitation	N/A	197	Europe	ATGAM plus CsA with or without Eltrombopag, hATG+CsA +/- Revolade	European Group for Blood and Marrow Transplantation	Severe Aplastic Anemia	12/33	12/34